These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19365880)

  • 1. Implication of bevacizumab in fatal arterial thromboembolic incidents.
    Grivas AA; Trafalis DT; Athanassiou AE
    J BUON; 2009; 14(1):115-7. PubMed ID: 19365880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM; Shah SR
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
    Heinzerling JH; Huerta S
    Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
    Roddy JV; Partridge SM; Rockey ML; Pruemer JM; Guo JJ; Desai SJ; Safa MM
    Am J Clin Oncol; 2010 Feb; 33(1):36-42. PubMed ID: 19652579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report].
    Mazières J; Dansin E
    Rev Pneumol Clin; 2008 Aug; 64(4):166-72. PubMed ID: 19019283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
    J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing bevacizumab-related toxicities in patients with colorectal cancer.
    Saif MW
    J Support Oncol; 2009; 7(6):245-51. PubMed ID: 20380333
    [No Abstract]   [Full Text] [Related]  

  • 11. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
    Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
    Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of bevacizumab in patients with metastatic breast cancer.
    Hamilton EP; Blackwell KL
    Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?
    Pereg D; Lishner M
    Eur Heart J; 2008 Oct; 29(19):2325-6. PubMed ID: 18762551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombo-embolic risks and bevacizumab: data from the literature and recommendations for the use of anticoagulants and antiaggregants].
    Senellart H; Bennouna J
    Rev Mal Respir; 2008 Oct; 25(8):1027-30. PubMed ID: 18971808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
    Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
    Krämer I; Lipp HP
    J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab: more fatal adverse effects.
    Prescrire Int; 2012 Nov; 21(132):266-7. PubMed ID: 23210257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.